With Intelligence Announces That Motive Partners Has Acquired a Majority Stake
20.7.2023 10:30:00 EEST | Business Wire | Press release
With Intelligence, a leading provider of investment data and intelligence for allocating, fund-raising and business development in the public and private markets, announced that it has received a majority investment from funds advised by Motive Partners (“Motive”), a specialist private equity firm focused on financial technology. Intermediate Capital Group ("ICG"), who originally invested in With Intelligence in 2020, will invest further alongside Motive. The investment is intended to serve as an accelerant for With Intelligence's growth, as the platform focuses on delivering leading connectivity, data and insights solutions to the Limited Partner and General Partner communities.
Founded in 1998, With Intelligence is a leading provider of data, intelligence and connectivity to the global asset management industry, with an integrated product suite of data, insights and events covering hedge funds, private credit, private equity, real estate and traditional asset management. Established 25 years ago, with over 500 employees and a geographic footprint across Europe, North America and Asia, With Intelligence has seen significant growth in recent years, with over 2,500 customers and a revenue compound annual growth rate of 33%.
With Intelligence blends data from a variety of the platform’s proprietary brands, delivering insights that include profiles, fund information, performance metrics and analyst perspectives. As the alternative investment landscape continues to evolve, With Intelligence is positioned to provide solutions that support mission-critical decision making across the fundraising and allocation lifecycle, for all participants in the value-chain. With Intelligence's strong growth is bolstered by a leading position in the hedge fund market, and is beginning to benefit from significant tailwinds driving the growth of private markets towards an estimated $15 trillion of assets under management in 2027.
Charlie Kerr, Founder & CEO at With Intelligence commented: “There is a huge opportunity for us to serve the global asset management industry during an exciting period of growth with greater data and analytics solutions than presently exist in the market. In order to capitalise on these tailwinds, we have chosen to partner with Motive Partners, who have a strong depth of expertise in financial technology across their group of Investors, Operators and Innovators. I am also grateful to ICG for their continued support and investment in the next phase of our growth journey.”
Neil Cochrane, Partner at Motive Partners commented: “We are positioned at the intersection of two exciting trends - the increase of allocations towards alternatives and the emergence of exciting new analytics and AI technologies to derive insights within the sector. Through the Motive IOI model and our extensive network, we are looking forward to capitalising on this market opportunity in partnership with Charlie, the With Intelligence team, and ICG.”
The investment by Motive and ICG will support With Intelligence to accelerate its data strategy and technology capabilities, continue to develop tailored offerings across various asset classes, grow the private markets offerings, and execute the next phase of the partnership and M&A strategies. It will also enable the company to further accelerate the pace of talent acquisition. Additionally, Motive's integrated operating model ("IOI model"), combining Investors, Operators and Innovators, will see a number of Motive team members collaborate with the With Intelligence team, including Charles Teschner (Industry Partner at Motive and the former CEO of Data and Analytics Solutions at BNY Mellon), Andy Stewart (Industry Partner at Motive, current CEO of Wilshire, and the former Co-Head of Blackrock's Alternative Investment Platform) and a team from Motive's innovation division, Motive Create.
“It has been a privilege to support the With Intelligence management team on their outstanding journey over the past few years, working alongside a visionary and entrepreneurial founder such as Charlie" said Jamie Rivers, Managing Director at ICG. Gareth Knight, Head of European Mid-Market at ICG added: "The company has a proven strategy for growth, and we're delighted to support the business for a further Investment cycle. We see Motive Partners being extremely well placed to help accelerate this over the coming years.”
Global investment banking firm Houlihan Lokey served as financial advisor to With Intelligence on the transaction, with other advisors including Proskauer (Legal), Financial & Tax (Alvarez & Marsal) and OC&C (Commercial). Arrowpoint Advisory, Joelson and Blick Rothenberg supported Management. Motive Partners' financial advisor was Raymond James, and they were also advised by MDW Capital Advisory (Debt Advisor), White & Case (Legal), Plural Strategy, Oliver Wyman (Commercial), and EY (Financial & Tax).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230720513739/en/
Contact information
With Intelligence
Louise Green, Chief Marketing Officer
louise.green@withintelligence.com
Motive Partners
Sam Tidswell-Norrish, Managing Director
sam@motivepartners.com
ICG
Clare Glynn, Head of Corporate Communications
clare.glynn@icgam.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Present New Data on ALYFTREK ® at the North American Cystic Fibrosis Conference9.10.2026 20:15:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine pancreatic function represent a profound shift in how we understand the benefits of treating cystic fibrosis in its earliest stages,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Devel
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 17:00:00 EEST | Press release
Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Stable Outlook from Fitch Ratings, assigned on 12 June 2026. Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation of the company’s
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 16:17:00 EEST | Press release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magic Quadrant confirms the shift has moved from pilot to boardroom priority. According to Gartner, Visionaries "understands where the market
Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 16:15:00 EEST | Press release
Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The valve features the company’s FREE next generation tissue treatment addressing the two main causes of calcification, phospholipids and aldehydes. Its proprietary LANCELOT advanced manufacturing process includes zero-pressure shaping and laser cutting of
Ada earns AWS Travel and Hospitality Competency for resolving traveler issues at scale9.10.2026 16:00:00 EEST | Press release
Ada, the pioneer in Agentic Customer Experience, today announced it has achieved the Amazon Web Services (AWS) Travel and Hospitality Competency. The designation recognizes Ada as an AWS Partner with demonstrated technical proficiency and proven customer success helping travel and hospitality brands resolve customer issues at scale. Ada joins a select group of 58 AWS Partners holding the competency, and it reflects a shared commitment to helping travel brands deliver service that holds up on their busiest, most unpredictable days. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009673638/en/ Ada earns AWS Travel and Hospitality Competency for resolving traveler issues at scale "Travel is where agentic customer service gets tested hardest. Demand spikes without warning, policies change by the hour, and customers are often stressed and far from home," said Mike Murchison, CEO and co-founder of Ada. "Our airline and hospitali
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
